Sichuan Biokin PharmaceuticalLtd Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Yi Zhu
Chief executive officer
CN¥2.5m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 74.4% |
| Management average tenure | no data |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
Does Sichuan Biokin PharmaceuticalLtd (SHSE:688506) Have A Healthy Balance Sheet?
Dec 27
Solid Earnings Reflect Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Strength As A Business
Nov 04Getting In Cheap On Sichuan Biokin Pharmaceutical Co.,Ltd. (SHSE:688506) Is Unlikely
Oct 29Sichuan Biokin PharmaceuticalLtd (SHSE:688506) Could Easily Take On More Debt
Aug 17Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Earnings May Just Be The Starting Point
May 03CEO
Yi Zhu (61 yo)
no data
Tenure
CN¥2,459,800
Compensation
Mr. Yi Zhu is Chairman, GM & Chief Scientific Officer of Sichuan Biokin Pharmaceutical Co.,Ltd. Mr. Zhu serves as Chairman, General Manager, Corporate Secretary and Chief Financial Officer of Systimmune, I...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | no data | CN¥2.46m | 74.35% CN¥ 54.9b | |
| CFO, Executive Deputy GM | no data | CN¥1.00m | 2.39% CN¥ 1.8b | |
| Deputy GM & Director | no data | CN¥698.90k | 0.062% CN¥ 45.8m | |
| Director | 7.3yrs | no data | no data | |
| Independent Director | 5.3yrs | CN¥120.00k | no data | |
| Employee-Representative Supervisor | 12.2yrs | CN¥75.00k | 0.0078% CN¥ 5.7m | |
| Director | 3.8yrs | CN¥1.27m | no data | |
| Independent Director | 4.1yrs | CN¥120.00k | no data | |
| Independent Director | 5.3yrs | CN¥120.00k | no data | |
| Chairman of the Supervisory Board | 1.8yrs | no data | no data | |
| Supervisor | 1.8yrs | no data | no data | |
| Director | less than a year | no data | no data |
4.1yrs
Average Tenure
53.5yo
Average Age
Experienced Board: 688506's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 17:17 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sichuan Biokin Pharmaceutical Co.,Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shitong Han | Citic Securities Co., Ltd. |
| Wenxin Yu | Haitong International Research Limited |